Vir Advances HBV, Flu Programs While Focused On COVID-19

Company Brought In Significant Cash Before And After Its IPO

 
• By Mandy Jackson
Hepatitis B
Vir has multiple COVID-19 programs, but its lead asset is for hepatitis B • Source: Shutterstock

More from Anti-infective

More from Therapeutic Category